Article
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
The oncologist - 1 Jan 2021
Cadranel Jacques, Liu Stephen V, Duruisseaux Michaël, Branden Eva, Goto Yasushi, Weinberg Benjamin A, Heining Christoph, Schlenk Richard F, Cheema Parneet, Jones Martin R, Drilon Alexander, Trombetta Domenico, Muscarella Lucia Anna, Tolba Khaled, Gounant Valerie, Cseh Agnieszka, Solca Flavio, Laskin Janessa J, Renouf Daniel J
Abstract excerpt
BACKGROUND: Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan-ErbB family inhibitor that may be an effective treatment for NRG1 fusion-driven tumors. PATIENTS AND METHODS: This report summarizes pertinent details, including best tumor response to treatment, for six patients with metastatic NRG1 fusion-positive tumors treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.